Biotech Investment Ltd Cpe ... Net Worth

Insiders trading at BeiGene Ltd

Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd.... y Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.

What does BeiGene Ltd do?

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

BeiGene Ltd executives and stock owners

BeiGene Ltd executives and other stock owners filed with the SEC include:

• John Oyler,
  Co-Founder, Executive Chairman of the Board, Chief Executive Officer
• Xiaodong Wang,
  Co-Founder, Non-Executive Director
• Dr. Xiaodong Wang Ph.D.,
  Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director
• John V. Oyler,
  Co-Founder, Exec. Chairman & CEO
• Dr. Xiaobin Wu Ph.D.,
  Pres, COO & GM of China
• Wang Lai,
  Global Head of R&D
• Dr. Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Jane Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Heng Liang,
  CFO & Chief Strategy Officer
• Thomas Malley,
  Non-Executive Independent Director
• Qingqing YI,
  Non-Executive Independent Director
• Timothy Chen,
  Non-Executive Independent Director
• Jing-Shyh Su,
  Non-Executive Independent Director
• Donald Glazer,
  Non-Executive Independent Director
• Ranjeev Krishana,
  Non-Executive Independent Director
• Michael Goller,
  Non-Executive Independent Director
• Corazon Sanders,
  Non-Executive Independent Director
• Anthony Hooper,
  Non-Executive Director
• Hing Ling Chau,
  Company Secretary
• Jane Huang,
  Chief Medical Officer, Hematology
• Xiaobin Wu,
  General Manager - China, President
• Kevin C. Mannix,
  Sr. VP of Investor Relations.
• Mi Zhou,
  Sr. Director of Investor Relations
• Julia Wang,
  CFO & Principal Accounting Officer
• Diana Lee Francis,
  VP and Global Head of Quality & Regulatory Compliance
• Scott Samuels,
  Sr. VP & Gen. Counsel
• Craig West CFA,
  Sr. Director of Investor Relations
• Michael Garvey,
  Global Head of Technical Operations
• Daniel Maller,
  VP of Fin. & Accounting
• Jianxin Yang,
  Sr. VP, Head of Clinical Dev.
• Amy C. Peterson,
  CMO, Immuno-oncology
• Ji Li,
  EVP and Gl. Head of Bus. Dev.
• Investment Management, Ltd....,
  10% owner
• Rui Rong Yuan,
  Chief Medical Officer
• Ke Tang,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Biotech Investment Ltd Cpe ...,
  
• Wendy Xiaojun Yan,
  Sr. VP, Head of Reg. Affairs
• & Co., Inc.Merck Sharp & Do...,
  
• Chan Henry Lee,
  SVP, General Counsel
• Bros. Advisors Lp14159, L.P...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Howard Liang,
  CFO & Chief Strategy Officer
• Inc Amgen,
  10% owner
• Lai Wang,
  Global Head of R&D
• Olivier Brandicourt,
  Director
• Julia Aijun Wang,
  Chief Financial Officer
• Margaret Dugan,
  Director
• Advisors, Ltd.Hillhouse Inv...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Titus B. Ball,
  Principal Accounting Officer
• Aaron Rosenberg,
  Chief Financial Officer